Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Item
http://www.wikidata.org/entity/Q34022231
Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulatorsGalantamine facilitates acquisition of a trace-conditioned eyeblink response in healthy, young rabbits.The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial.Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies.Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment.Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease.Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease.Histochemical study of acute and chronic intraperitoneal nicotine effects on several glycolytic and Krebs cycle dehydrogenase activities in the frontoparietal cortex and subcortical nuclei of the rat brain.Galantamine: a new treatment for Alzheimer's disease.Chronic nicotine administration increases NGF-like immunoreactivity in frontoparietal cerebral cortex.Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study.Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease.PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats.Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
P2860

Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease.

Item
http://www.wikidata.org/entity/Q34022231
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@ast
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@en
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@nl
type
label
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@ast
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@en
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@nl
prefLabel
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@ast
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@en
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@nl
P1433
P1476
P2093
P304
P31
P356
P478
P577
P698
P921
P356
P1433
P1476
Allosteric modulation of nicot ...... ategy for Alzheimer's disease.
@en
P2093
P304
P31
P356
P478
P577
P698
P921